An update on bimatoprost in glaucoma therapy

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 12, 2002, Pages 1753-1762

  Cantor, Louis B ^a  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bimatoprost; Glaucoma; Intraocular pressure; Ocular hypertension; Prostamide; Target pressure

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHAGAN P; ANTIGLAUCOMA AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BIMATOPROST; BRIMONIDINE; BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; DORZOLAMIDE; LATANOPROST; PILOCARPINE; PILOPINE HS; PROSTAGLANDIN DERIVATIVE; TIMOLOL; TIMOLOL MALEATE; TRAVOPROST;

ADJUVANT THERAPY; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; EYE PROTECTION; EYELASH; HEADACHE; HEART DISEASE; HERPES SIMPLEX KERATITIS; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRIS DISEASE; LONG TERM CARE; NONHUMAN; OPEN ANGLE GLAUCOMA; PROGNOSIS; RETINA MACULA CYSTOID EDEMA; RETINA MACULA EDEMA; REVIEW; RISK ASSESSMENT; VISUAL FIELD; VISUAL IMPAIRMENT;

AMIDES; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; CLINICAL TRIALS; DRUG COMBINATIONS; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; LIPIDS; OMEPRAZOLE; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS F, SYNTHETIC; SULFONAMIDES; THIOPHENES;

EID: 0036931954     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.12.1753     Document Type: Review

References (57)

1. QUIGLEY HA: Number of people with glaucoma worldwide. Br. J. Ophthalmol. (1996) 80:389-393.
2. THYLEFORS B, NÉGREL AD: The global impact of glaucoma. Bull. World Health Org. (1994) 72:323-326.
3. MAO LK, STEWART WC, SHIELDS MB: Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am. J. Ophthalmol. (1991) 111:51-55.
4. LICHTER PR, MUSCH DC, GILLESPIE BW et al.: Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomized to medications or surgery. Ophthalmology (2001) 108:1943-1953.
5. SHIRAKASHI M, IWATA K, SAWAGUCHI S, ABE H, NANBA K: Intraocular pressure-dependent progression of visual field loss in advanced primary open-angle glaucoma: a 15-year follow-up. Ophthalmologica (1993) 207:1-5.
6. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am. J. Ophthalmol. (2000) 130:429-440.
7. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-tension Glaucoma Study Group. Am. J. Ophthalmol. (1998) 126:487-497. Published erratum appears in Am. J. Ophthalmol. (1999) 127:120.
8. GONZALEZ I, PABLO LE, PUEYO M et al.: Assessment of diurnal tensional curve in early glaucoma damage. Int. Ophthalmol. (1996-97) 20:113-115.
9. ASRANI S, ZEIMER R, WILENSKY J, GIESER D, VITALE S, LINDENMUTH K: Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J. Glaucoma (2000) 9:134-142.
10. SPAETH GL, MARQUES PEREIRA ML: How does resetting intraocular pressure help optic nerve function? Eye (2000) 14:476-487.
11. KASS MA, GORDON MO, HOFF MR et al.: Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals. A randomized, double-masked, long-term clinical trial. Arch. Ophthalmol. (1989) 107:1590-1598.
12. EPSTEIN DL, KRUG JH Jr, HERTZMARK E, REMIS LL, EDELSTEIN DJ: A long-term clinical trial of timolol therapy versus no treatment in the management of glaucoma suspects. Ophthalmology (1989) 96:1460-1467.
13. SCHULZER M, DRANCE SM, DOUGLAS GR: A comparison of treated and untreated glaucoma suspects. Ophthalmology (1991) 98:301-307.
14. KASS MA, HEUER DK, HIGGINBOTHAM EJ et al.: The ocular hypertension treatment study: a randomized trial determines that topical medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. (2002) 120:701-713.
15. LUI JHK, KRIPKE DF, TWA MD et al.: Twenty-four-hour pattern of intraocular pressure in the aging population. Invest. Ophthalmol. Vis. Sci. (1999) 40:2912-2917.
16. DAVID R, ZANGWILL L, BRISCOE D, DAGAN M, YAGEV R, YASSUR Y: Diurnal intraocular pressure variations: an analysis of 690 diurnal curves. Br. J. Ophthalmol. (1992) 76:280-283.
17. SACCA SC, ROLANDO M, MARLETTA A et al.: Fluctuations of intraocular pressure during the day in open-angle glaucoma, normal-tension glaucoma and normal subjects. Ophthalmologica (1998) 212:115-119.
18. ZEIMER RC, WILENSKY JT, GIESER DK: Presence and rapid decline of early morning intraocular pressure peaks in glaucoma patients. Ophthalmology (1990) 97:547-550.
19. BRUBAKER RF: Mechanism of action of bimatoprost (Lumigan). Surv. Ophthalmol. (2001) 45(Suppl. 4):S347-S351.
20. SINGH K, SPAETH G, ZIMMERMAN T, MINCKLER D: Target pressure - glaucomatologists' holey grail. Ophthalmology (2000) 107:629-630.
21. ZEYEN T: Target pressures in glaucoma. Bull. Soc. Belge. Ophtalmol. (1999) 274:61-65.
22. American Academy of Ophthalmology Preferred Practice Pattem™: Primary Open-Angle Glaucoma. (2000).
23. CANTOR LB: Bimatoprost: a member of a new class of agents, the prostamides, for glaucoma management. Expert Opin. Investig. Drugs. (2001) 10(4):721-731.
24. DIGGORY P, FRANKS W. Medical treatment of glaucoma - a reappraisal of the risks. Br. J. Ophthalmol. (1996) 80:85-89.
25. GRANT WM: Clinical measurements of aqueous outflow. Arch. Ophthalmol. (1951) 46:113-131.
26. BECKER B: Comment on: large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J. Glaucoma. (2000) 9(6):487-488.
27. WOODWARD DF, KRAUSS AH-P, CHEN J et al.: The pharmacology of bimatoprost (Lumigan™). Surv. Ophthalmol. (2001) 45(Suppl. 4):S337-S345.
28. LAIBOVITZ RA, VANDENBURGH AM, FELIX C et al: Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy and safety evaluation of a novel compound for glaucoma management. Arch. Ophthalmol. (2001) 119(7):994-1000.
29. DUBINER H, COOKE D, DIRKS M, STEWART WC, VANDENBURGH AM, FELIX C: Efficacy and safety of bimatoprost in patients with elevated IOP: a 30-day comparison with latanoprost. Surv. Ophthalmol. (2001) 45(Suppl. 4):S353-S360.
30. BRANDT JD, VANDENBURGH AM, CHEN K, WHITCUP SM: Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology (2001) 108(6):1023-1031.
31. SHERWOOD M, BRANDT J: Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated inrraocular pressure. Surv. Ophthalmol. (2001) 45(Suppl. 4):S361-S368.
32. BRUBAKER RF, SCHOFF EO, NAU CB et al.: Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am. J. Ophthalmol. (2001) 131:19-24.
33. SHARIF NA, WILLIAMS GW, KELLY CR. Bimatoprost and its free acid are prostaglandin FP receptor agonists. Eur. J. Pharmacol. (2001) 432:211-213.
34. WANG R-F, SERLE JB, GAGLIUSO D, MITTAG TW, PODOS TW: Effect of latanoprost (L) or bimatoprost (B) alone and in combination on intraocular pressure (IOP) in glaucomatous monkey eyes. Presented at the Annual Meeting of the Association for Vision Research and Ophthalmology. Fort Lauderdale, FL, USA (2002):4070.
35. 2α by rabbit and monkey ocular tissues, in vivo. Presented at the Annual Meeting of the Association for Vision Research and Ophthalmology Fort Lauderdale, FL, USA (2002):4109.
36. WOODWARD DF, MADHU C, BURK RM et al.: AGN 192024 (Lumigan™): a synthetic prostamide analog that lowers primate intraocular pressure by virtue of its inherent pharmacological activity. Presented at the Annual Meeting of the Association for Vision Research and Ophthalmology. Fort Lauderdale, FL, USA (2002):4110.
37. MAXEY KM, JOHNSON J, CAMRAS CB, LABRECQUE J: The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Presented at the Annual Meeting of the American Glaucoma Society. San Juan, Puerto Rico (2002).
38. KRAUSS AH-P, CHEN J, ANDREWS SW, TANG-LIU D, NILSSON SFE, WOODWARD DF: The ocular pharmacology and bioavailability of AGN 192024 (Lumigan™), a novel ocular hypotensive agent. Presented at the Annual Meeting of the Association for Vision Research and Ophthalmology. Fort Lauderdale, FL USA (2001):4465.
39. SJOQUIST B, JOHANSSON A, STJERNSCHANTZ J: Pharmacokinetics of latanoprost in the cynomolgus monkey. 3rd communication: tissue distribution after topical administration on the eye studied by whole body autoradiography. Arzneimittelforschung (1999) 49:240-249.
40. CHEETHAM JK, TANG-LIU D, YU Z et al.: Long-term systemic exposure of Lumigan in patients with glaucoma or ocular hypertension. Presented at the Annual Meeting of the Association for Vision Research and Ophthalmology. Fort Lauderdale, FL, USA (2002):4108.
41. HIGGINBOTHAM EJ, GOLDBERG I, SCHUMAN JS et al.: One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch. Ophthalmol. (2002) 120:1286-1293.
42. GANDOLFI S, SIMMONS ST, STURM R, CHEN K, VANDENBURGH AM: Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv. Ther. (2001) 18(3):110-121.
43. NOECKER RS, DIRKS MS, CHOPLIN NT, BERNSTEIN P, BATOOSINGH AL, WHITCUP SM: A six-month randomized clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. The Bimatoprost/Latanoprost Study Group. Am. J. Ophthalmol. (2003): (In press).
44. COLEMAN AL, VANDENBURGH AM, BERNSTEIN P, WHITCUP SM: A 3-month comparison of bimatoprost (Lumigan™) with timolol/dorzolamide (Cosopt™) in patients with glaucoma or ocular hypertension. Presented at the American Academy of Ophthalmology. New Orleans, LA, USA (2000):322.
45. WALTERS TR, DUBINER HB, CARPENTER S, VANDENBURGH AM: 24-Hour diurnal comparison of once-daily dosing with bimatoprost 0.03%, timolol-XE™, and latanoprost 0.005%. Presented at the American Academy of Ophthalmology. New Orleans, LA, USA (2001):233.
46. DIRKS MS: Bimatoprost as monotherapy in patients previously treated with timolol/latanoprost dual therapy. Presented at the Annual Meeting of the American Glaucoma Society. (2002) San Juan, Puerto Rico.
47. MELAMED S, BOSSAWSKA I, LAROCH C; BIMATOPROST ADJUNCTIVE TO TIMOLOL STUDY GROUP: Effectiveness of bimatoprost (LUMIGAN™) as adjunctive therapy with topical β-blockers in patients with glaucoma or ocular hypertension: a 3-month, multicenter, double-masked, randomized, vehicle-controlled trial with double-masked extension of bimatoprost treatment to 1 year. Presented at the Annual Meeting of the Association for Vision Research and Ophthalmology. Fort Lauderdale, FL, USA (2002):1068.
48. FRENKEL REP: Efficacy of bimatoprost 0.03% as adjunctive therapy in glaucoma patients using latanoprost 0.005%. Presented at the Annual Meeting of the American Glaucoma Society. San Juan, Puerto Rico (2002).
49. LEE DA, GROSS R, MUNDORF TK; LUMIGAN EARLY EXPERIENCE STUDY GROUP: Efficacy and safety of bimatoprost 0.03% (LUMIGAN™) in a large-scale, open-label clinical trial. Presented at the Annual Meeting of the Association for Vision Research and Ophthalmology. Fort Lauderdale, FL, USA (2002):4105.
50. WAND M, GAUDIO AR: Cystoid macular edema associated with ocular hypotensive lipids. Am. J. Ophthalmol. (2002) 133(3):403-405.
51. KROLL DM, SCHUMAN JS: Reactivation of herpes simplex virus keratitis after initiating bimatoprost treatment for glaucoma. Am. J. Ophthalmol. (2002) 133(3):401-403.
52. SCHERER WJ: A retrospective review of non-responders to latanoprost. J. Ocul. Pharmacol. Ther. (2002) 18(3):287-291.
53. NETLAND PA. LANDRY T, SULLIVAN K et al.: Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol. (2001) 132:472-484.
54. 2α analog, on aqueous humor dynamics in human eyes. Ophthalmology (1993) 100:1297-1304.
55. SAITO M, TAKANO R, SHIRATO S: Effects of latanoprost and unoprostone when used alone or in combination for open-angle glaucoma. Am. J. Ophthalmol. (2001) 132:485-489.
56. 2α analogue, after topical application in normal and ocular hypertensive human eyes. Arch. Ophthalmol. (1993) 111:1351-1358.
57. MORGAN PV, PRONIUK S, BLANCHARD J, NOECKER RJ: Effect of temperature and light on the stability of latanoprost and its clinical relevance. J. Glaucoma. (2001) 10:401-405.